Discovery at Warp Speed
Total Page:16
File Type:pdf, Size:1020Kb
DANA-FARBER CANCER INSTITUTE 2016 HONOR ROLL OF DONORS DISCOVERY AT WARP SPEED 5 DRUGS IN 5 WEEKS ON THE COVER CONTENTS Discovery at Warp Speed: 5 Drugs in 5 Weeks A Message from Early in fiscal year 2016, in a span of five weeks, the U.S. Food and the President & CEO of Dana-Farber Cancer Institute . 1 Drug Administration (FDA) gave approval to five new cancer drugs that A Message from proved their effectiveness in Dana-Farber–led clinical trials—and, in the Senior Vice President for Development ............. 2 some cases, derived from basic research in Dana-Farber laboratories. A Message from These approvals mark advances in the treatment of several major the Trustee Development Committee Chair ............. 3 types of cancer, including soft-tissue sarcomas, non-small cell lung Institute Benefactors ................................. 4 cancer, and multiple myeloma. The Dana-Farber–led science and New Commitments ................................... 8 testing of these agents covered the full range of drug development— Edward J. Benz Jr., MD, Chair ........................ 10 from earliest discovery and phase 1 studies to large-scale phase 3 clinical trials. Individuals. 13 President’s Circle .................................... 30 Most of the new drugs are the first of their kind to be approved for these specific types of cancer, and represent novel applications of Trustee Giving ...................................... 31 precision medicine, combination therapy, or immunotherapy. For Corporations, Foundations, Organizations & Trusts ..... 34 example, ixazomib—one of the trio of new myeloma drugs Boston Red Sox ..................................... 44 approved—is the first oral agent of its type and is used in combination New England Patriots & New England Revolution ...... 46 with two other drugs to treat patients who have received at least one prior therapy. An international phase 3 trial for patients with recurrent Corporate Programs ................................ 48 or drug-resistant myeloma showed that the disease could be controlled Planned Gifts ....................................... 53 longer by adding this new agent to the treatment regimen. Dana-Farber Society ................................. 54 “We have seen an unprecedented pace Tribute & Memorial Gifts ............................. 57 of progress in myeloma therapy this Named Funds ....................................... 61 year,” said Paul Richardson, MD (left), Leadership Committees ............................. 67 clinical program leader and director of clinical research at Dana-Farber’s Faculty Awards & Honors ............................ 70 Jerome Lipper Multiple Myeloma Center Pan-Mass Challenge ................................. 72 and LeBow Institute for Myeloma Special Events ...................................... 76 Therapeutics, R.J. Corman Professor of Jimmy Fund Golf .................................... 80 Medicine, and the senior clinical investigator in all three of these drug approvals. “The results from Running Programs .................................. 84 these studies emanate from basic science led by Dana-Farber Boston Marathon® Jimmy Fund Walk ................. 86 researchers. These are first successfully translated to the clinic and Palm Beach ......................................... 88 then tested to confirm efficacy as a key part of the approval process, Friends of Dana-Farber Cancer Institute ............... 90 and so reflect the real benefits our patients can anticipate from Kraft Family Blood Donor Center ..................... 92 these advances.” Volunteers .......................................... 95 And this was just the beginning. Throughout 2016, additional treatments developed at Dana-Farber earned FDA approval. About Dana-Farber & the Jimmy Fund ................. 96 Learn about two of them on pages 16 and 26. FACULTY RESEARCH FUND UPDATE and leukemia research to advance cancer treatments for patients. These For the fiscal year ending September 30, 2016 monies bolstered the Institute’s investment in treatment strategies that Since its inception, Dana-Farber Cancer Institute has placed an emphasis on harness the power of the immune system and genetics to fight cancer, and cancer research and its applications to improve cancer outcomes. This commitment precision cancer medicine approaches that focus on targeted therapies by means that research is prominent in all of the Institute’s strategic decisions. The disease, gene, and mutation. creation of a Faculty Research Fund in 2013 was an institutional initiative designed In fiscal year 2016, support for the Faculty Research Fund totaled to help Dana-Farber achieve its ambitious research agenda. Since its launch, the $4.4 million. These funds will be applied to the build-out of the Longwood Faculty Research Fund has raised $14.1 million, which is especially important as Center. This allocation is pivotal to providing the Institute’s chemical biology, federal funding for cancer research remains competitive. structural biology, proteomics, and applied cancer science programs with Support totaling $3.8 million to the Faculty Research Fund received in 2015 state-of-the-art laboratories and technologies that accelerate the pace of was applied in 2016 to Dana-Farber’s initiatives in immunotherapy, genomics, drug discovery and play a crucial role in Dana-Farber’s lifesaving mission. Welcome A MESSAGE FROM THE PRESIDENT & CEO OF DANA-FARBER CANCER INSTITUTE Dear Friends, In my first months as President and CEO of Dana-Farber, I have been continually impressed by the incredible passion and talent all around me. From our researchers, physicians, and management, to our wonderful supporters, the level of dedication I’ve experienced is unparalleled. In 2016, we made important progress across the Institute, and I would like to recognize some of the work made possible by your partnership. During this pivotal time in cancer medicine, Dana-Farber continues to lead the way through cutting-edge scientific investigations and top-tier patient care, as exemplified by our Profile program. The largest and most comprehensive patient-based genomics project in the world, Profile leverages the latest genetic sequencing technologies to “We are unyielding in our pinpoint the alterations driving each patient’s cancer. This knowledge can empower our physician-scientists to select promising therapies that target individual mutations, shared goal: to reduce the a form of care called precision medicine. Excitingly, we were the first—and remain burden of cancer for patients the only—institution that attempts to acquire a genetic profile for each patient who enters our doors, allowing us to better understand their cancer and identify and their families.” personalized treatments. Your support has also empowered our investigators to remain global pioneers in developing cancer immunotherapies, which activate the power of the human immune system. Thanks in large part to studies led by Dana-Farber, new FDA- approved drugs and agents in clinical trials can unleash the body’s natural defenses against cancer. Our teams are dedicated to understanding why certain tumors do not respond to existing therapies, and are developing novel drugs and promising combination therapies to help patients who need more options. Already during my leadership at Dana-Farber, I have had several remarkable experiences that I consider among the highlights of my career. I was tremendously proud to be part of Vice President Biden’s Cancer Moonshot Blue Ribbon Panel, through which we developed recommendations that will expedite lifesaving discoveries. I was also honored to be present as President Obama signed the 21st Century Cures Act, which will provide $1.8 billion to drive cancer research. Dana-Farber’s inclusion in these groundbreaking national efforts reflects our well- deserved reputation for excellence, and I look forward to upholding this legacy in the years ahead. Thank you for your generosity, which is enabling these advances and many more throughout Dana-Farber. Whether by finding new treatments in the laboratory, caring for patients in the clinic, or supporting and advocating for research, we are unyielding in our shared goal: to reduce the burden of cancer for patients and their families. Sincerely, Laurie H. Glimcher, MD 10% of all designated gifts supports our Faculty Research Fund to advance Dana-Farber’s research mission. 1 Welcome A MESSAGE FROM THE SENIOR VICE PRESIDENT FOR DEVELOPMENT Dear Friends, The year just past was one of tremendous progress at Dana-Farber. Several new drugs that originated in our labs or proved their effectiveness in our clinical trials were approved by the FDA. New drug combinations, targeted therapies, and cancer immunotherapies were discovered. And much more—all to improve outcomes for our patients and their families. Helping to drive all this progress was an equally tremendous outpouring of support from you, our generous donors. In fiscal year 2016, more than 286,000 individuals, families, foundations, organizations, and events made gifts totaling an amazing $228.1 million to support our lifesaving mission. Several multimillion-dollar gifts provided the cornerstone for this incredible total. “Every single gift, large or Among these are a visionary investment of $20 million in the Bridge Project by the Commonwealth Foundation for Cancer Research, which will drive new small, translates into hope treatments for the most resistant cancers, and a transformative $15 million gift for our patients and families from Institute